Boehringer Ingelheim and 3BP Forge a Multi-Year Collaboration

Boehringer Ingelheim and privately-held 3B Pharmaceuticals GmbH (3BP) forged a multi-year peptide-led drug discovery collaboration.

In a brief announcement from Berlin-based 3BP, the smaller company will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets selected by the larger Boehringer Ingelheim. 3BP said hit compounds identified will be “further optimized and jointly characterized by both companies.”